Galapagos discovers novel class of antibiotics that kill all MRSA strains

11/27/2012 | Examiner.com

Belgian biotech firm Galapagos said it has identified a new class of antibiotics that demonstrate strong activity against drug-resistant strains of Staphylococcus aureus, including MRSA. The antibiotic acts against an enzyme that is key to the growth of all bacteria, the company said. Galapagos said clinical studies could begin for the antibiotic candidate CAM-1 in early 2014.

View Full Article in:

Examiner.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC